<p>Truist Financial Corp 在最近向證券交易委員會（SEC）提交的文件中表示，在第四季度將其在 Emergent BioSolutions Inc.（紐約證券交易所代碼：EBS - 免費報告）的股份減少了 40.9%。該基金在此期間出售了 59,003 股後，持有該生物製藥公司 85,193 股股票。Truist Financial Corp 在最近一個季度末持有的 Emergent BioSolutions 的股份價值 814,000 美元，佔其總股份的 0.16%。</p>
<p>獲取 <strong>Emergent BioSolutions</strong> 警報：</p>
<ul>
<li>在市場輪動持續的情況下，關注這 4 只超買股票</li>
</ul>
<p>其他對沖基金最近也調整了對該公司的持股。Stifel Financial Corp 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 96,000 美元。FORA Capital LLC 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 103,000 美元。Landscape Capital Management L.L.C. 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 141,000 美元。Entropy Technologies LP 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 155,000 美元。最後，B. Riley Wealth Advisors Inc. 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 295,000 美元。78.40% 的股票由機構投資者和對沖基金持有。</p>
<h2>Emergent BioSolutions 股票表現</h2>
<p>Emergent BioSolutions 股票週五開盤價為 7.46 美元。該公司的市值為 4.0394 億美元，市盈率為 -1.82，貝塔值為 1.62。該公司的 50 日移動平均價格為 9.54 美元，200 日移動平均價格為 9.06 美元。該公司的債務與股本比率為 1.30，流動比率為 2.88，速動比率為 1.47。Emergent BioSolutions Inc. 的 12 個月最低價為 1.82 美元，最高價為 15.10 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>EBS 已成為幾份研究報告的主題。Benchmark 在 11 月 7 日的報告中將 Emergent BioSolutions 的目標股價從 8.00 美元上調至 12.00 美元，並給予該公司 &#34;買入&#34; 評級。StockNews.com 在 2 月 17 日的報告中將 Emergent BioSolutions 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。最後，HC Wainwright 在 1 月 21 日的報告中重申了 &#34;買入&#34; 評級，並對 Emergent BioSolutions 的目標股價設定為 15.00 美元。</p>
<p><strong>查看我們對 Emergent BioSolutions 的最新股票分析</strong></p>
<h2>Emergent BioSolutions 公司簡介</h2>
<p>（免費報告）</p>
<p>Emergent BioSolutions Inc. 是一家生命科學公司，提供針對美國意外、故意和自然發生的公共健康威脅的應急準備和響應解決方案。該公司提供 NARCAN 鼻用噴霧劑用於已知或疑似阿片類藥物過量的緊急治療；Vaxchora 疫苗用於預防霍亂；Vivotif 疫苗用於口服給藥以預防傷寒；Anthrasil 用於吸入性炭疽的治療；BioThrax，一種炭疽疫苗；CYFENDUS 用於在懷疑或確認接觸炭疽芽孢桿菌後進行疾病的暴露後預防；以及 Raxibacumab 注射劑用於吸入性炭疽的治療和預防。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而非 Emergent BioSolutions</li>
<li>如何購買股票：初學者的逐步指南</li>
<li>Autodesk 為投資者設計的價值：上升趨勢將持續</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>安海斯 - 布希股票反彈——啤酒之王迴歸了嗎？</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>MarketBeat 週迴顧 – 02/24 - 02/28</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Emergent BioSolutions 嗎？</h2>
<p>在你考慮 Emergent BioSolutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Emergent BioSolutions 並不在名單上。</p>
<p>雖然 Emergent BioSolutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>Truist Financial Corp 在第四季度將其在 Emergent BioSolutions Inc. (NYSE:EBS) 的持股減少了 40.9%，在出售了 59,003 股後，現持有 85,193 股。該公司的市值為 814,000 美元。其他對沖基金也增加了他們的持倉。Emergent 的股票開盤價為 7.46 美元，市值為 4.0394 億美元，市盈率為 -1.82。分析師們提高了價格目標，Benchmark 將其從 8.00 美元上調至 12.00 美元，並維持 “買入” 評級</p>

<p>Truist Financial Corp reduced its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,193 shares of the biopharmaceutical company's stock after selling 59,003 shares during the period. Truist Financial Corp owned 0.16% of Emergent BioSolutions worth $814,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Truist Financial Corp 在最近向證券交易委員會（SEC）提交的文件中表示，在第四季度將其在 Emergent BioSolutions Inc.（紐約證券交易所代碼：EBS - 免費報告）的股份減少了 40.9%。該基金在此期間出售了 59,003 股後，持有該生物製藥公司 85,193 股股票。Truist Financial Corp 在最近一個季度末持有的 Emergent BioSolutions 的股份價值 814,000 美元，佔其總股份的 0.16%。</p>
</div><p>Get <strong>Emergent BioSolutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Emergent BioSolutions</strong> 警報：</p>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>在市場輪動持續的情況下，關注這 4 只超買股票</li>
</ul>
</div><p>Other hedge funds also recently modified their holdings of the company. Stifel Financial Corp purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $103,000. Landscape Capital Management L.L.C. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $141,000. Entropy Technologies LP purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $155,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Emergent BioSolutions during the 3rd quarter worth about $295,000. 78.40% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金最近也調整了對該公司的持股。Stifel Financial Corp 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 96,000 美元。FORA Capital LLC 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 103,000 美元。Landscape Capital Management L.L.C. 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 141,000 美元。Entropy Technologies LP 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 155,000 美元。最後，B. Riley Wealth Advisors Inc. 在第三季度購買了 Emergent BioSolutions 的新股份，價值約 295,000 美元。78.40% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Emergent BioSolutions Stock Performance</h2>
<div class="lb-trans"><h2>Emergent BioSolutions 股票表現</h2>
</div><p>Emergent BioSolutions stock opened at $7.46 on Friday. The company has a market cap of $403.94 million, a PE ratio of -1.82 and a beta of 1.62. The company has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $9.06. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10.</p>
<div class="lb-trans"><p>Emergent BioSolutions 股票週五開盤價為 7.46 美元。該公司的市值為 4.0394 億美元，市盈率為 -1.82，貝塔值為 1.62。該公司的 50 日移動平均價格為 9.54 美元，200 日移動平均價格為 9.06 美元。該公司的債務與股本比率為 1.30，流動比率為 2.88，速動比率為 1.47。Emergent BioSolutions Inc. 的 12 個月最低價為 1.82 美元，最高價為 15.10 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>EBS has been the topic of several research reports. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. StockNews.com upgraded shares of Emergent BioSolutions from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Monday, February 17th. Finally, HC Wainwright restated a &#34;buy&#34; rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, January 21st.</p>
<div class="lb-trans"><p>EBS 已成為幾份研究報告的主題。Benchmark 在 11 月 7 日的報告中將 Emergent BioSolutions 的目標股價從 8.00 美元上調至 12.00 美元，並給予該公司 &#34;買入&#34; 評級。StockNews.com 在 2 月 17 日的報告中將 Emergent BioSolutions 的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。最後，HC Wainwright 在 1 月 21 日的報告中重申了 &#34;買入&#34; 評級，並對 Emergent BioSolutions 的目標股價設定為 15.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Emergent BioSolutions</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Emergent BioSolutions 的最新股票分析</strong></p>
</div><h2>Emergent BioSolutions Profile</h2>
<div class="lb-trans"><h2>Emergent BioSolutions 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.</p>
<div class="lb-trans"><p>Emergent BioSolutions Inc. 是一家生命科學公司，提供針對美國意外、故意和自然發生的公共健康威脅的應急準備和響應解決方案。該公司提供 NARCAN 鼻用噴霧劑用於已知或疑似阿片類藥物過量的緊急治療；Vaxchora 疫苗用於預防霍亂；Vivotif 疫苗用於口服給藥以預防傷寒；Anthrasil 用於吸入性炭疽的治療；BioThrax，一種炭疽疫苗；CYFENDUS 用於在懷疑或確認接觸炭疽芽孢桿菌後進行疾病的暴露後預防；以及 Raxibacumab 注射劑用於吸入性炭疽的治療和預防。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Emergent BioSolutions</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>Autodesk Designs Value for Investors: Uptrend Set to Continue</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Anheuser-Busch Stock Rallies—Is the King of Beers Back?</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>MarketBeat Week in Review – 02/24 - 02/28</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Emergent BioSolutions</li>
<li>如何購買股票：初學者的逐步指南</li>
<li>Autodesk 為投資者設計的價值：上升趨勢將持續</li>
<li>除了喝咖啡，還有 3 種投資咖啡的方法</li>
<li>安海斯 - 布希股票反彈——啤酒之王迴歸了嗎？</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>MarketBeat 週迴顧 – 02/24 - 02/28</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EBS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Emergent BioSolutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Emergent BioSolutions 嗎？</h2>
</div><p>Before you consider Emergent BioSolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Emergent BioSolutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent BioSolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Emergent BioSolutions 並不在名單上。</p>
</div><p>While Emergent BioSolutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Emergent BioSolutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Emergent BioSolutions Inc. (NYSE:EBS) 的股票被 Truist Financial Corp 出售